From idea to practice.

Apart from its own patent-protected technology platform, the Swiss pharmaceutical company InnoMedica is defined above all through the will of a team to develop from innovative research in the field of nanotransport systems and to bring them to patients. To achieve this goal, experienced entrepreneurs and managers work side by side with university graduates and young talents. Only the joint efforts of employees, investors, physicians and ultimately patients will make it possible to master the path to a prescription drug.

About InnoMedica

What started as a start-up with a founding team of five key people has evolved into a pharmaceutical company with its own certified Nanofactory and over 50 employees.

Team

Experienced entrepreneurs and scientists work together to bring InnoMedica's innovative medicine to patients in the shortest possible timeframe.

Investors

InnoMedica has developed into a public company in recent years. Through annual share offerings the shareholder base has grown to more than 950 shareholders.

Job & Career

A team of creative thinking innovators combined with expertise and patient proximity. Apply now and actively contribute to the company's future success.

Media reports

Here you will find a selection of media coverage on InnoMedica and our projects.

Statements

Statements on Our Work

News

Most Recent Updates

Mai 2021

Interview mit Prof. Dr. Smita Saxena zu Talineuren bei ALS

The application for the first clinical trial with Talineuren, InnoMedica’s drug in the field of neurology, …

Read more

May 2021

Talineuren: Clinical trial application submitted

InnoMedica has reached an important milestone with the submission of the first Clinical Trial Application for …

Read more

March 2021

ODD for Talineuren and capital increase 2021

Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) approved InnoMedica’s …

Read more